CTCFL expression is associated with cerebral vascular abnormalities

CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention

(2020) Elena M. Pugacheva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTCF and CTCFL in cancer

(2020) Roxanne E Debaugny et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

CCM3 and cerebral cavernous malformation disease

(2019) Kang Wang et al.   JOURNAL OF INVESTIGATIVE MEDICINE

BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14

(2019) Joanna C Hillman et al.   MOLECULAR CANCER RESEARCH

Postzygotic mosaicism in cerebral cavernous malformation

(2019) Matthias Rath et al.   JOURNAL OF MEDICAL GENETICS

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells

(2019) David N. Debruyne et al.   NATURE

The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer

(2019) Marisol Salgado-Albarrán et al.   Oncogenesis

Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain

(2018) Sergey I. Nikolaev et al.   NEW ENGLAND JOURNAL OF MEDICINE

Choice of binding sites for CTCFL compared to CTCF is driven by chromatin and by sequence preference

(2018) Philipp Bergmaier et al.   NUCLEIC ACIDS RESEARCH

Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia

(2018) Ludmila Pawlikowska et al.   Molecular Genetics & Genomic Medicine

BORIS: a key regulator of cancer stemness

(2018) Sara Soltanian et al.   Cancer Cell International

Targeting CTCFL/BORIS for the immunotherapy of cancer

(2018) Dmitri Loukinov   CANCER IMMUNOLOGY IMMUNOTHERAPY

Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility

(2018) Tae Nam Kim et al.   Genes & Genomics

Vis-à-vis: a focus on genetic features of cerebral cavernous malformations and brain arteriovenous malformations pathogenesis

(2018) Concetta Scimone et al.   NEUROLOGICAL SCIENCES

The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes

(2017) Evgeny Teplyakov et al.   Oncotarget

Discovering a binary CTCF code with a little help from BORIS

(2017) Victor V. Lobanenkov et al.   Nucleus

Discovering a binary CTCF code with a little help from BORIS

(2017) Victor V. Lobanenkov et al.   Nucleus

Introduction to cerebral cavernous malformation: a brief review

(2016) Jaehong Kim   BMB Reports

Molecular, Cellular, and Genetic Determinants of Sporadic Brain Arteriovenous Malformations

(2016) Brian P. Walcott et al.   NEUROSURGERY

The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements

(2016) Elena M. Pugacheva et al.   Epigenetics & Chromatin

PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk

(2015) Svetlana M. Stamatovic et al.   ACTA NEUROPATHOLOGICA

KLF4 is a key determinant in the development and progression of cerebral cavernous malformations

(2015) R. Cuttano et al.   EMBO Molecular Medicine

Expression of theCTCFLGene during Mouse Embryogenesis Causes Growth Retardation, Postnatal Lethality, and Dysregulation of the Transforming Growth Factor β Pathway

(2015) Leyla Sati et al.   MOLECULAR AND CELLULAR BIOLOGY

Sulindac metabolites decrease cerebrovascular malformations inCCM3-knockout mice

(2015) Luca Bravi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mouse Models of Cerebral Arteriovenous Malformation

(2015) Corinne M. Nielsen et al.   STROKE

Brain arteriovenous malformations

(2015) Michael T. Lawton et al.   Nature Reviews Disease Primers

A Common Polymorphism within the IGF2 Imprinting Control Region Is Associated with Parent of Origin Specific Effects in Infantile Hemangiomas

(2015) Brent Schultz et al.   PLoS One

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene

(2015) Erling A. Hoivik et al.   Oncotarget

Quantitative Analysis of Histological Staining and Fluorescence Using ImageJ

(2014) Ellen C. Jensen   Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology

Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations

(2014) Robert Shenkar et al.   GENETICS IN MEDICINE

Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis

(2014) David A. McDonald et al.   HUMAN MOLECULAR GENETICS

EndMT contributes to the onset and progression of cerebral cavernous malformations

(2013) Luigi Maddaluno et al.   NATURE

Expression of the cancer-testis antigen BORIS correlates with prostate cancer

(2013) Zubair Cheema et al.   PROSTATE

Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

(2012) Koji Okabayashi et al.   CANCER SCIENCE

BORIS, Brother of the Regulator of Imprinted Sites, Is Aberrantly Expressed in Hepatocellular Carcinoma

(2012) Kefei Chen et al.   Genetic Testing and Molecular Biomarkers

Age-Dependent Lethality in Novel Transgenic Mouse Models of Central Nervous System Arteriovenous Malformations

(2012) Ian Milton et al.   STROKE

The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner

(2012) Frank Sleutels et al.   Epigenetics & Chromatin

BORIS in human cancers – A review

(2011) Irena Martin-Kleiner   EUROPEAN JOURNAL OF CANCER

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice

(2011) Aubrey C. Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

Cerebral cavernous malformations: from genes to proteins to disease

(2011) Daniel D. Cavalcanti et al.   JOURNAL OF NEUROSURGERY

In Vitro Characterization of the Angiogenic Phenotype and Genotype of the Endothelia Derived From Sporadic Cerebral Cavernous Malformations

(2011) Yuan Zhu et al.   NEUROSURGERY

Loss ofcerebral cavernous malformation 3(Ccm3) in neuroglia leads to CCM and vascular pathology

(2011) Angeliki Louvi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inactivation of Smad4 leads to impaired ocular development and cataract formation

(2010) Ying Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Molecular architecture of CTCFL

(2010) Amy E. Campbell et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease

(2010) D. A. McDonald et al.   HUMAN MOLECULAR GENETICS

Expression of a Testis-Specific Form of Gal3st1 (CST), a Gene Essential for Spermatogenesis, Is Regulated by the CTCF Paralogous Gene BORIS

(2010) T. Suzuki et al.   MOLECULAR AND CELLULAR BIOLOGY

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells

(2010) S. Renaud et al.   NUCLEIC ACIDS RESEARCH

A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells

(2008) Axel Pagenstecher et al.   HUMAN MOLECULAR GENETICS

Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis

(2008) Amy L. Akers et al.   HUMAN MOLECULAR GENETICS

Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development

(2008) M. Monk et al.   MOLECULAR HUMAN REPRODUCTION

Expression ofBORISin melanoma: Lack of association withMAGE-A1activation

(2007) Olga Kholmanskikh et al.   INTERNATIONAL JOURNAL OF CANCER